Navamedic rights issue prospectus approved, subscription period opens next week

Navamedic ASA announced today, September 19, 2025, that the Financial Supervisory Authority of Norway has approved its prospectus for a contemplated partly underwritten rights issue. The company aims to raise gross proceeds of between NOK 110 million and NOK 130 million.

The prospectus covers the listing of up to 6,046,511 offer shares and an additional 272,090 new shares for the settlement of underwriting fees. The subscription period for the rights issue is set to commence on September 22, 2025, at 09:00 CEST and will close on October 6, 2025, at 16:30 CEST.

Subscription rights will be tradable on the Oslo Stock Exchange from September 22, 2025, until September 30, 2025. DNB Carnegie and Nordea Corporate Finance have been retained as managers for the rights issue, with Advokatfirmaet Thommessen AS acting as Norwegian legal counsel.